Literature DB >> 32344034

How Brazil Is Dealing with COVID-19 Pandemic Arrival Regarding Elective Gynecological Surgeries.

Luiz Gustavo Oliveira Brito1, Paulo Ayrosa Ribeiro2, Agnaldo Lopes Silva-Filho3.   

Abstract

Entities:  

Year:  2020        PMID: 32344034      PMCID: PMC7194702          DOI: 10.1016/j.jmig.2020.04.028

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


× No keyword cloud information.
To the Editor: Brazil, a continental country with 210 million people, is starting to have an increase in the number of infected cases and in mortality owing to the coronavirus disease (COVID-19) outbreak that started in February [1]. Whereas the pandemic has spread worldwide, and our curve is weeks behind other epicenters such as the United States, Italy, and Spain, our main obstetric and gynecologic society (Brazilian Federation of Gynecology and Obstetrics Associations) and several affiliated societies (e.g., Brazilian Association of Urogynecology and Pelvic Floor and Brazilian Endometriosis and Minimally Invasive Society) have been preparing to counsel our members. Several nonpharmaceutical interventions were oriented nationally [2], and discussions between healthcare providers and decision makers have helped several hospitals [3] before the explosion of cases. Obstetric and oncology services had a smaller reduction in cases than services that are mainly referred for elective surgeries. We have prepared documents in a frequently asked questions format for counseling gynecologic surgeons to reschedule elective surgeries for benign diseases [4], discussed implementing telemedicine in many outpatient clinics, and analyzed how to reorganize surgical scenarios for gynecologic oncology patients and/or emergency surgeries. However, we are still facing many regional barriers such as lack of massive testing for patients, either asymptomatic or symptomatic; disparities between the number of COVID-19 patients admitted in public intensive care units (ICUs) versus private ICUs (and also the number of available ICUs throughout the country); possible underreporting of national data for several reasons; and most importantly not all facilities have sufficient personal protective equipments. Our guidelines are aligned with the joint statement previously published on the American Association of Gynecologic Laparoscopists website with several societies [5] recommending that elective surgeries should be postponed or rescheduled, and that this should be a joint decision between surgeon and patient; that the risk factors for COVID-19 should be discussed with the patient; and that the absence of COVID-19 symptoms should exhaustively be confirmed in case the patient needs to undergo a surgery. Testing should be massively encouraged before surgery. Within the operating room, N-95 masks (as well as the rest of the accessories: shoe covers, gown, protective head covering, gloves, and eye protection) should be guaranteed for the surgical team, the number of personnel inside the operating room should be restricted, and there should be a conversation with the anesthesia team before each procedure. For vaginal and abdominal surgeries, the use of N-95 masks plus face shields should be mandatory and smoke dispersion should be avoided as much as possible. Regarding laparoscopic procedures, they can be performed if, after informed consent is obtained from the patient, the entire operating room team has access to the necessary personal protective equipments and extreme care is taken to reduce pneumoperitoneum escape [6]. It is important to remember that at this moment, no data are available proving that COVID-19 viral particles were identified in surgical smoke. Finally, most urogynecological disorders can be treated conservatively. We are still uncertain whether we are flattening the curve, and discussions about reopening elective surgeries are still controversial; however, we believe that we are ready to fight this battle, and we are extensively advising patients to seek out hospitals if their symptoms are worsening during the quarantine.
  5 in total

1.  Nonpharmaceutical interventions for tackling the COVID-19 epidemic in Brazil.

Authors:  Leila Posenato Garcia; Elisete Duarte
Journal:  Epidemiol Serv Saude       Date:  2020-04-09

2.  Perspectives on Surgery in the Time of COVID-19: Safety First.

Authors:  Sarah L Cohen; Grace Liu; Mauricio Abrao; Neil Smart; Todd Heniford
Journal:  J Minim Invasive Gynecol       Date:  2020-04-03       Impact factor: 4.137

3.  COVID-19 in Latin America: The implications of the first confirmed case in Brazil.

Authors:  Alfonso J Rodriguez-Morales; Viviana Gallego; Juan Pablo Escalera-Antezana; Claudio A Méndez; Lysien I Zambrano; Carlos Franco-Paredes; Jose A Suárez; Hernan D Rodriguez-Enciso; Graciela Josefina Balbin-Ramon; Eduardo Savio-Larriera; Alejandro Risquez; Sergio Cimerman
Journal:  Travel Med Infect Dis       Date:  2020-02-29       Impact factor: 6.211

4.  How should health systems prepare for the evolving COVID-19 pandemic? Reflections from the perspective of a Tertiary Cancer Center.

Authors:  Andre Tsin Chih Chen; Camila Motta Venchiarutti Moniz; Ulysses Ribeiro-Júnior; Maria Del Pilar Estevez Diz; João Victor Salvajoli; Karina Gondim Moutinho Da Conceição Vasconcelos; José Otávio Costa Auler-Júnior; Ivan Cecconello; Edson Abdala; Paulo Marcelo Gehm Hoff
Journal:  Clinics (Sao Paulo)       Date:  2020-04-06       Impact factor: 2.365

5.  Joint Statement on Minimally Invasive Gynecologic Surgery during the COVID-19 Pandemic.

Authors: 
Journal:  J Minim Invasive Gynecol       Date:  2020-05-24       Impact factor: 4.137

  5 in total
  2 in total

1.  JMIG during the COVID-19 Crisis: Drawing on our International Expertise.

Authors:  Gary N Frishman; Tommaso Falcone
Journal:  J Minim Invasive Gynecol       Date:  2020-05-18       Impact factor: 4.137

Review 2.  Impact of COVID-19 in Female Urology.

Authors:  Paulo Cesar Rodrigues Palma; Luiz Gustavo Oliveira Brito; Joanna Ghigo
Journal:  Int Braz J Urol       Date:  2020-07       Impact factor: 1.541

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.